Compass Therapeutics Announces FDA Feedback on tovecimig in BTC

What Happened
Compass Therapeutics, Inc. (CMPX) filed a Form 8-K on September 22, 2026 (Item 7.01) disclosing a press release that reports regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding tovecimig in patients with biliary tract cancer (BTC). The full press release is attached to the filing as Exhibit 99.1.

Key Details

• Date of disclosure: September 22, 2026 (Form 8-K, Regulation FD disclosure).
• Drug/indication: tovecimig in biliary tract cancer (BTC).
• Press release included as Exhibit 99.1 to the Form 8-K.
• Filing category: Item 7.01 (Regulation FD Disclosure); Exhibits listed under Item 9.01.

Why It Matters
Regulatory feedback from the FDA is material to a drug developer because it can affect clinical development plans, regulatory strategy, and timelines — all of which influence investor expectations for future value and milestones. Investors should watch for follow-up communications from Compass Therapeutics for details on the FDA’s comments and any announced changes to clinical programs or timelines.